A degradable soybean-based biomaterial used effectively as a bone filler in vivo in a rabbit.
The 'gold standard' for bone filling is currently the bone autograft, but its use is limited by material availability and by the possible risks of infection or other donor site morbidity. Materials proposed so far as bone fillers do not show all the characteristics which are desirable. These are (a) osteoconductivity, (b) controlled biodegradation and (c) ease of adaptation to the implantation site. Recently, a new class of biodegradable material based on soybeans has been presented which shows good mechanical properties and an intrinsic bioactivity on inflammatory and tissue cells in vitro. The authors investigated the morphology in vivo of bone response in repairing a surgical lesion in the presence of granules of a novel soybean-based biomaterial (SB), comparing it with a sham-operated contralateral lesion of critical size (non-healing model); 26 operations were performed in New Zealand White rabbits, with back scattered electron microscopy as the analysis technique of choice. Implantation of SB granules over 8 weeks produced bone repair with features distinct from those obtained by healing in a non-treated defect. New and progressively maturing trabeculae appeared in the animal group where SB granules were implanted, while sham operation produced only a rim of pseudo-cortical bone still featuring a large defect. The trabeculae forming in the presence of SB granules had features typical of reticular bone. These findings suggest that the bone regeneration potential of SB granules and their intrinsic bioactivity, combined with their relatively easy and cost-effective preparation procedures, make them suitable candidates as a bone filler in clinical applications.
Merolli
Antonio
A
Department of Orthopaedic Surgery, The Catholic University in Rome, Complesso Columbus, via Moscati 31, 00168 Rome, Italy.
Nicolais
Luigi
L
Ambrosio
Luigi
L
Santin
Matteo
M
D020341:Absorbable Implants; D000818:Animals; D018786:Bone Substitutes / Q000627:therapeutic use*; D005264:Femoral Fractures / Q000473:pathology* / Q000628:therapy*; D008422:Materials Testing; D010936:Plant Extracts / Q000627:therapeutic use*; D011817:Rabbits; D013025:Glycine max / Q000737:chemistry*; D016896:Treatment Outcome
D018786:Bone Substitutes; D010936:Plant Extracts